NASDAQ · TSVT
Healthcare · Biotechnology
$5.00
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 4:48 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
TSVT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning TSVT.
TSVT research
Company profile and research snapshot.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 14, 2025 | Morgan Stanley | Equal-Weight | — |
| Mar 11, 2025 | Leerink Partners | Market Perform | — |
| Jul 29, 2024 | Morgan Stanley | Equal-Weight | — |
| Jun 27, 2024 | Wedbush | Neutral | — |
| May 9, 2024 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 9, 2024
2seventy bio, Inc. announced it will discontinue enrollment in its Phase 3 KarMMa-9 study, citing an improved treatment landscape and a review of the business case. This news led to a sharp drop in the company's stock price.
Zacks Investment Research · May 6, 2024
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
Zacks Investment Research · May 2, 2024
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Zacks Investment Research · Apr 25, 2024
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TSVT.
No results
No recent SID articles mention TSVT.
